Literature DB >> 14583574

Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.

I Tchetverikov1, L R Lard, J DeGroot, N Verzijl, J M TeKoppele, F C Breedveld, T W J Huizinga, R Hanemaaijer.   

Abstract

OBJECTIVE: To analyse the relation between systemic levels of pro-MMP-3, -8, and -9 matrix metalloproteinase (MMP) activity in alpha(2) macroglobulin (alpha(2)M)/MMP complexes and the progression of joint destruction in patients with recent onset rheumatoid arthritis (RA).
METHODS: 109 patients with RA of recent onset were entered into this longitudinal study. Patients were followed up for two years; clinical data, blood samples, and radiographs were obtained at baseline and at 1 and 2 years. Serum levels of MMPs were measured by sandwich ELISA and MMP activity assays.
RESULTS: During the two years joint damage progressed from 0 to 10 (median Sharp score, p<0.001). Stable levels of pro-MMP-3 and a significant decrease in the levels of pro-MMP-8 and -9 and alpha(2)M/MMP complexes were seen throughout the two years. Regression analysis showed that serum pro-MMP-3 levels at disease onset were independently associated with the progression of joint damage (B=0.7, 95% CI 0.3 to 1.1, p=0.001). Based on the rate of joint destruction, patients were divided into two subgroups: patients with mild and severe joint damage progression. The pro-MMP-3 levels were significantly higher in the group with severe compared with mild disease at all times. Levels of pro-MMP-8 and -9 were decreased in both groups, whereas alpha(2)M/MMP complex levels decreased in the group with mild disease only.
CONCLUSION: Serum levels of the MMPs studied are associated with disease activity, but serum pro-MMP-3 levels at the onset of disease are also predictive of joint damage progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583574      PMCID: PMC1754368          DOI: 10.1136/ard.62.11.1094

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

1.  Correlation among macrophage inflammatory protein 1alpha levels, matrix metalloproteinase 8 levels, and systemic inflammation in rheumatoid arthritis: comment on the articles by Yamanaka et al and Mattey et al.

Authors:  W C Kullich; G Klein
Journal:  Arthritis Rheum       Date:  2001-12

2.  Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.

Authors:  G Cunnane; O Fitzgerald; C Beeton; T E Cawston; B Bresnihan
Journal:  Arthritis Rheum       Date:  2001-10

Review 3.  Alpha 2-macroglobulin.

Authors:  A J Barrett
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

4.  Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Authors:  C Ribbens; M Martin y Porras; N Franchimont; M-J Kaiser; J-M Jaspar; P Damas; F A Houssiau; M G Malaise
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

5.  Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage.

Authors:  L R Lard; M Boers; A Verhoeven; K Vos; H Visser; J M W Hazes; A H Zwinderman; G M T Schreuder; F C Breedveld; R R P De Vries; S van der Linden; E Zanelli; T W J Huizinga
Journal:  Arthritis Rheum       Date:  2002-04

6.  Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis.

Authors:  Philippe E Van den Steen; Paul Proost; Bernard Grillet; David D Brand; Andrew H Kang; Jo Van Damme; Ghislain Opdenakker
Journal:  FASEB J       Date:  2002-03       Impact factor: 5.191

7.  Expression of proteinases and inflammatory cytokines in subchondral bone regions in the destructive joint of rheumatoid arthritis.

Authors:  M Kaneko; T Tomita; T Nakase; Y Ohsawa; H Seki; E Takeuchi; H Takano; K Shi; K Takahi; E Kominami; Y Uchiyama; H Yoshikawa; T Ochi
Journal:  Rheumatology (Oxford)       Date:  2001-03       Impact factor: 7.580

8.  The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism.

Authors:  A J Barrett; P M Starkey
Journal:  Biochem J       Date:  1973-08       Impact factor: 3.857

9.  Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.

Authors:  R Goldbach-Mansky; J M Lee; J M Hoxworth; D Smith; P Duray; R H Schumacher; C H Yarboro; J Klippel; D Kleiner; H S El-Gabalawy
Journal:  Arthritis Res       Date:  2000-02-09

Review 10.  Matrix metalloproteinases in arthritic disease.

Authors:  Gillian Murphy; Vera Knäuper; Susan Atkinson; George Butler; William English; Mike Hutton; Jan Stracke; Ian Clark
Journal:  Arthritis Res       Date:  2002-05-09
View more
  43 in total

1.  Accelerated atherosclerosis in patients with Wegener's granulomatosis.

Authors:  K de Leeuw; J-S Sanders; C Stegeman; A Smit; C G Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2004-09-16       Impact factor: 19.103

2.  Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis?

Authors:  Salih Pay; Hakan Erdem; Aysel Pekel; Ismail Simsek; Ugur Musabak; Ali Sengul; Ayhan Dinc
Journal:  Rheumatol Int       Date:  2005-10-05       Impact factor: 2.631

3.  Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis.

Authors:  Aruna K Behera; Ethan Hildebrand; Joanna Scagliotti; Allen C Steere; Linden T Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.

Authors:  I Kirman; S Jain; V Cekic; A Belizon; E Balik; P Sylla; T Arnell; K A Forde; R L Whelan
Journal:  Surg Endosc       Date:  2006-01-21       Impact factor: 4.584

5.  Matrix Metalloproteinases-3 Baseline Serum Levels in Early Rheumatoid Arthritis Patients without Initial Radiographic Changes: A Two-Year Ultrasonographic Study.

Authors:  Slavica Z Prodanovic; Goran Radunovic; Dragan Babic; Biljana Ristic; Mirjana Sefik-Bukilica; Maja Zlatanovic; Katarina Simic-Pasalic; Srdjan Seric; Nada Vujasinovic-Stupar; Janko Samardzic; Nemanja Damjanov
Journal:  Med Princ Pract       Date:  2018-05-24       Impact factor: 1.927

6.  Matrix metalloproteinase-9 inhibition reduces inflammation and improves motility in murine models of postoperative ileus.

Authors:  Beverley A Moore; Carl L Manthey; Dana L Johnson; Anthony J Bauer
Journal:  Gastroenterology       Date:  2011-06-22       Impact factor: 22.682

Review 7.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

8.  Knockdown of sphingosine kinase 1 inhibits the migration and invasion of human rheumatoid arthritis fibroblast-like synoviocytes by down-regulating the PI3K/AKT activation and MMP-2/9 production in vitro.

Authors:  Hongxia Yuan; Pingting Yang; Dun Zhou; Wei Gao; Zhenyu Qiu; Fang Fang; Shuang Ding; Weiguo Xiao
Journal:  Mol Biol Rep       Date:  2014-05-10       Impact factor: 2.316

Review 9.  The role of biomarkers in the management of patients with rheumatoid arthritis.

Authors:  Jackie Nam; Edith Villeneuve; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

10.  Inducible nitric oxide synthase deficiency impairs matrix metalloproteinase-9 activity and disrupts leukocyte migration in hepatic ischemia/reperfusion injury.

Authors:  Takashi Hamada; Sergio Duarte; Seiichiro Tsuchihashi; Ronald W Busuttil; Ana J Coito
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.